Biotage Joins Forces with MultiSynTech and Enters the Peptide Synthesis Business
News Feb 24, 2009
Biotage announced that the company will enter the peptide synthesis business, through two new agreements with German company MultiSynTech GmbH. The agreements concern both the distribution rights for MultiSynTechs systems and the establishment of a joint development project.
The agreements with MultiSynTech will grant Biotage distribution rights for all current MultiSynTech peptide synthesis systems. Biotage and MultiSynTech have also agreed on a joint development project to design and market a new microwave-aided peptide synthesis system, which will increase yield and speed in peptide synthesis.
Demand for synthetic peptides is currently growing rapidly. The peptide synthesizer market is estimated at SEK 150m and is growing at double digit rate. In the research phase, biochemists need increasingly longer, more complex peptides to study protein interactions, produce peptide antibodies, and understand complex disease states. As the number and complexity of peptides increase, the biochemists need new tools that offer higher productivity and increased performance.
The Biotage - MultiSynTech collaboration will create those new tools that University and biopharmaceutical peptide research groups and contract peptide labs need to meet the new challenges in peptide synthesis. Biotage will be uniquely positioned to offer both parallel synthesis and microwave synthesis capability to address the full range of needs.
We look forward to working in close collaboration with Biotage. Biotage has a proven sales and support team that dramatically expands our coverage outside Central Europe, and really opens opportunities for our current products in USA, UK, Nordic and Asian regions, says Udo Treffer, CEO of MultiSynTech.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE